Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Background Women benefit from reduced fracture risk while using menopausal hormone therapy. However, information on risks after stopping menopausal hormone therapy is scarce and inconsistent, with no information on longer-term fracture risk as women age. We aimed to produce robust estimates of fracture risk among past users for the longest possible period after discontinuing therapy.

More information Original publication

DOI

https://doi.org/10.1016/j.lanhl.2025.100729

Type

Journal article

Journal

The Lancet

Issue

The Lancet Healthy Longevity, Volume 6, Issue 7, 100729

Publisher

Elsevier Ltd

Publication Date

23/07/2025

Addresses

This project was funded by the National Institute for Health and Care Research (NIHR) School for Primary Care Research (SPCR) (grant number: 617).